Brain O
connectivity O
alterations O
in O
early O
psychosis O
: O
from O
clinical O
to O
neuroimaging O
staging O
Early O
in O
the O
course O
of O
psychosis O
, O
alterations O
in O
brain O
connectivity O
accompany O
the O
emergence O
of O
psychiatric O
symptoms O
and O
cognitive O
impairments O
, O
including O
processing O
speed O
. O

The O
clinical-staging O
model O
is O
a O
refined O
form O
of O
diagnosis O
that O
places O
the O
patient O
along O
a O
continuum O
of O
illness O
conditions O
, O
which O
allows O
stage-specific O
interventions O
with O
the O
potential O
of O
improving O
patient O
care O
and O
outcome O
. O

This O
cross-sectional O
study O
investigates O
brain O
connectivity O
features O
that O
characterize O
the O
clinical O
stages O
following O
a O
first O
psychotic O
episode O
. O

Structural O
brain O
networks O
were O
derived O
from O
diffusion-weighted O
MRI O
for O
71 O
early-psychosis O
patients O
and O
76 O
healthy O
controls O
. O

Patients O
were O
classified O
into O
stage O
II O
( O
first-episode O
) O
, O
IIIa O
( O
incomplete O
remission O
) O
, O
IIIb O
( O
one O
relapse O
) O
, O
and O
IIIc O
( O
two O
or O
more O
relapses O
) O
, O
according O
to O
the O
course O
of O
the O
illness O
until O
the O
time O
of O
scanning O
. O

Brain O
connectivity O
measures O
and O
diffusion O
parameters O
( O
fractional O
anisotropy O
, O
apparent O
diffusion O
coefficient O
) O
were O
investigated O
using O
general O
linear O
models O
and O
sparse O
linear O
discriminant O
analysis O
( O
sLDA O
) O
, O
studying O
distinct O
subgroups O
of O
patients O
who O
were O
at O
specific O
stages O
of O
early O
psychosis O
. O

We O
found O
that O
brain O
connectivity O
impairments O
were O
more O
severe O
in O
clinical O
stages O
following O
the O
first-psychosis O
episode O
( O
stages O
IIIa O
, O
IIIb O
, O
IIIc O
) O
than O
in O
first-episode O
psychosis O
( O
stage O
II O
) O
patients O
. O

These O
alterations O
were O
spatially O
diffuse O
but O
converged O
on O
a O
set O
of O
vulnerable O
regions O
, O
whose O
inter-connectivity O
selectively O
correlated O
with O
processing O
speed O
in O
patients O
and O
controls O
. O

The O
sLDA O
suggested O
that O
relapsing-remitting O
( O
stages O
IIIb O
, O
IIIc O
) O
and O
non-remitting O
( O
stage O
IIIa O
) O
patients O
are O
characterized O
by O
distinct O
dysconnectivity O
profiles O
. O

Our O
results O
indicate O
that O
neuroimaging O
markers O
of O
brain O
dysconnectivity O
in O
early O
psychosis O
may O
reflect O
the O
heterogeneity O
of O
the O
illness O
and O
provide O
a O
connectomics O
signature O
of O
the O
clinical-staging O
model O
. O

Materials O
and O
methods O
Subjects O
A O
total O
of O
147 O
subjects O
( O
71 O
early-psychosis O
patients O
( O
EPPs O
) O
and O
76 O
healthy O
controls O
( O
HCs O
) O
) O
were O
included O
in O
this O
cross-sectional O
study O
( O
Table O
1 O
) O
. O

The O
71 O
EPPs O
( O
49 O
males O
, O
26.0 O
± O
6.2yo O
) O
were O
recruited O
from O
an O
early O
intervention O
program O
( O
Treatment O
and O
Early O
Intervention O
in O
Psychosis O
Program O
( O
TIPP O
) O
) O
of O
the O
Lausanne O
University O
Hospital O
, O
Switzerland O
. O

The O
entry O
criteria O
into O
the O
TIPP O
were O
the O
following O
: O
between O
18 O
and O
35 O
years O
of O
age O
; O
residence O
in O
the O
catchment O
area O
; O
and O
meeting O
the O
threshold O
criteria O
for O
psychosis O
according O
to O
CAARMS O
psychosis-threshold O
subscale O
. O

A O
total O
of O
76 O
age O
, O
gender O
and O
handedness-matched O
HCs O
( O
48 O
males O
, O
26.7 O
± O
6.1yo O
) O
were O
recruited O
from O
the O
same O
catchment O
area O
; O
they O
were O
not O
affected O
by O
any O
mood O
, O
psychotic O
or O
substance-use O
disorder O
and O
had O
no O
first-degree O
relative O
with O
a O
psychotic O
disorder O
. O

A O
history O
of O
neurological O
disorder O
, O
severe O
head O
trauma O
or O
mental O
retardation O
( O
IQ O
< O
70 O
) O
were O
exclusion O
criteria O
for O
all O
subjects O
. O

All O
of O
the O
participants O
provided O
informed O
written O
consent O
for O
this O
study O
, O
and O
the O
procedure O
was O
approved O
by O
the O
Ethics O
Committee O
of O
Clinical O
Research O
of O
the O
Faculty O
of O
Biology O
and O
Medicine O
, O
University O
of O
Lausanne O
, O
Switzerland O
. O

Clinical O
staging O
The O
clinical O
stage O
was O
rated O
as O
the O
highest O
stage O
achieved O
at O
the O
time O
of O
imaging O
. O

The O
patients O
were O
stratified O
into O
four O
distinct O
groups O
( O
stages O
II O
and O
IIIa-c O
( O
Fig O
. O

1 O
) O
) O
based O
on O
a O
consensus O
assessment O
by O
two O
experienced O
psychiatrists O
, O
according O
to O
the O
clinical-staging O
model O
proposed O
by O
McGorry O
and O
colleagues O
. O

Any O
unclear O
issue O
was O
discussed O
with O
the O
case-managers O
. O

The O
subjects O
in O
stage O
II O
were O
first-episode O
psychosis O
patients O
, O
with O
one O
psychotic O
episode O
according O
to O
the O
CAARMS O
psychosis-threshold O
subscale O
and O
no O
past O
episodes O
at O
the O
time O
of O
the O
study O
( O
i.e. O
, O
discrete O
disorder O
) O
. O

Patients O
in O
stage O
III O
were O
defined O
as O
follows O
: O
IIIa O
: O
incomplete O
remission O
from O
stage O
II O
at O
12 O
months O
after O
entry O
to O
care O
and O
following O
a O
reasonable O
course O
of O
treatment O
( O
> O
3 O
months O
) O
, O
with O
duration O
of O
illness O
no O
longer O
than O
5 O
years O
; O
IIIb O
: O
recurrence O
or O
relapse O
of O
a O
psychotic O
episode O
( O
i.e. O
, O
discrete O
disorder O
has O
fully O
recovered O
but O
then O
relapsed O
to O
the O
full O
extent O
described O
in O
stage O
II O
) O
; O
IIIc O
: O
two O
or O
more O
relapses O
after O
stage O
II O
with O
remission O
between O
episodes O
. O

Further O
details O
on O
the O
patients O
’ O
assessment O
can O
be O
found O
in O
SI.1 O
. O

Other O
clinical O
and O
cognitive O
assessments O
In O
patients O
, O
the O
symptoms O
severity O
was O
assessed O
with O
the O
Positive O
and O
Negative O
Syndrome O
Scale O
( O
PANSS O
) O
, O
and O
the O
functioning O
level O
was O
assessed O
with O
the O
Global O
Assessment O
of O
Functioning O
( O
GAF O
) O
scale O
. O

For O
each O
patient O
, O
a O
consensus O
diagnosis O
was O
realized O
by O
a O
senior O
psychiatrist O
and O
a O
senior O
psychologist O
in O
charge O
of O
scale-based O
assessment O
over O
the O
treatment O
period O
, O
based O
on O
DSM-IV O
criteria O
. O

The O
levels O
of O
cannabis O
and O
alcohol O
use O
were O
assessed O
with O
the O
Case O
Manager O
Rating O
Scale O
( O
CMRS O
) O
and O
ranked O
as O
none O
, O
mild O
, O
moderate O
, O
severe O
or O
extremely O
severe O
. O

None O
of O
the O
patients O
had O
extremely O
sever O
level O
of O
cannabis O
or O
alcohol O
use O
. O

Antipsychotic O
doses O
were O
converted O
to O
chlorpromazine O
equivalents O
. O

All O
of O
the O
subjects O
were O
assessed O
with O
the O
MATRICS O
Consensus O
Cognitive O
Battery O
. O

MRI O
measurements O
and O
connectome O
reconstruction O
Each O
subject O
underwent O
an O
MR-imaging O
session O
on O
a O
3-Tesla O
Siemens O
scanner O
, O
including O
magnetization-prepared O
rapid O
acquisition O
gradient O
echo O
( O
MPRAGE O
) O
sequence O
( O
1-mm O
in-plane O
resolution O
, O
1.2-mm O
slice O
thickness O
) O
and O
diffusion O
spectrum O
imaging O
( O
DSI O
) O
sequences O
( O
257 O
diffusion-weighted O
volumes O
and O
1 O
b0 O
volume O
, O
maximum O
b-value O
8000 O
s/mm2 O
, O
2.2 O
× O
2.2 O
× O
3 O
mm3 O
resolution O
) O
. O

During O
the O
study O
, O
there O
was O
a O
routine O
MRI-system O
upgrade O
from O
the O
MAGNETOM-Trio O
to O
the O
MAGNETOM-Prisma O
Siemens O
system O
. O

Imaging O
parameters O
were O
precisely O
matched O
before O
and O
after O
the O
upgrade O
, O
and O
the O
same O
32-channel O
head O
coil O
was O
used O
. O

Individual O
connectomes O
were O
estimated O
by O
combining O
MPRAGE O
and O
DSI O
data O
. O

Briefly O
, O
MPRAGE O
volumes O
were O
segmented O
into O
WM O
, O
GM O
and O
cerebrospinal O
fluid O
compartments O
. O

The O
GM O
was O
parcellated O
into O
82 O
( O
68 O
cortical O
and O
14 O
subcortical O
) O
regions O
based O
on O
the O
Desikan-Killiany O
atlas O
. O

Reconstructed O
DSI-data O
were O
used O
to O
compute O
generalized O
fractional O
anisotropy O
( O
gFA O
) O
and O
apparent O
diffusion O
coefficient O
( O
ADC O
) O
scalar O
maps O
, O
and O
for O
deterministic O
streamline O
tractography O
. O

The O
structural O
connectivity O
between O
each O
pair O
of O
cortical O
and O
subcortical O
regions O
was O
quantified O
as O
the O
number O
of O
streamlines O
connecting O
the O
two O
regions O
, O
which O
resulted O
in O
82-nodes O
, O
weighted O
undirected O
brain-networks O
. O

For O
consistency O
reasons O
and O
to O
limit O
possible O
biases O
in O
the O
network O
analyses O
, O
connections O
that O
were O
present O
in O
less O
than O
50 O
% O
of O
the O
subjects O
were O
discarded O
. O

Further O
details O
regarding O
MRI O
acquisitions O
’ O
parameters O
, O
data O
processing O
and O
connectome O
reconstruction O
can O
be O
found O
in O
the O
SI.2 O
, O
SI.3 O
. O

Brain O
connectivity O
measures O
Global O
and O
nodal O
( O
i.e. O
, O
specific O
to O
single O
brain O
regions O
) O
connectivity O
measures O
were O
considered O
. O

The O
overall O
brain O
network O
strength O
was O
quantified O
as O
the O
total O
streamline O
count O
in O
the O
network O
. O

The O
centrality O
of O
each O
brain O
region O
in O
the O
network O
was O
quantified O
with O
the O
nodal O
strength O
, O
which O
was O
defined O
as O
the O
weighted O
sum O
of O
the O
node O
’ O
s O
connections O
. O

Tract-average O
gFA O
and O
ADC O
values O
were O
computed O
for O
each O
connection O
of O
individual O
brain O
networks O
. O

gFA O
and O
ADC O
values O
relate O
to O
organizational O
and O
microstructural O
properties O
of O
the O
WM O
, O
including O
myelination O
levels O
, O
axonal O
packing O
and O
fibre O
coherence O
. O

The O
network O
efficiency O
and O
clustering O
coefficient O
were O
investigated O
in O
supplementary O
analyses O
( O
SI.8 O
, O
Figure O
S4−S5 O
) O
. O

Statistical O
methods O
Statistical O
differences O
between O
the O
subjects O
’ O
groups O
were O
assessed O
with O
multi-factor O
ANCOVA O
within O
a O
general O
linear O
model O
( O
GLM O
) O
framework O
. O

Age O
, O
gender O
, O
handedness O
and O
a O
‘ O
scanner-upgrade O
’ O
variable O
were O
added O
as O
co-variates O
in O
all O
of O
the O
analyses O
. O

Global O
network O
analyses O
were O
repeated O
on O
data O
acquired O
on O
the O
MAGNETOM-Trio O
or O
on O
the O
MAGNETOM-Prisma O
system O
only O
to O
further O
exclude O
major O
effects O
of O
the O
scanner O
upgrade O
on O
the O
results O
. O

The O
effect O
size O
was O
quantified O
with O
the O
Cohen O
’ O
s O
d O
coefficient O
between O
GLM O
residual O
distributions O
, O
after O
correcting O
for O
covariates O
. O

Continuous O
variables O
’ O
cross-group O
progression O
was O
tested O
with O
the O
Jonckheere-Terpstra O
( O
JT O
) O
test O
for O
ordered O
alternative O
hypotheses O
. O

The O
false O
discovery O
rate O
correction O
for O
multiple O
comparisons O
was O
applied O
when O
indicated O
. O

Logistic O
regression O
was O
used O
to O
assess O
the O
cognitive O
impairments O
( O
MATRICS O
scores O
) O
of O
patients O
with O
respect O
to O
healthy O
controls O
( O
see O
SI.4 O
) O
. O

Relationships O
between O
neuroimaging O
and O
clinical/cognitive O
variables O
were O
assessed O
with O
Pearson O
’ O
s O
correlation O
coefficient O
( O
r O
) O
. O

A O
sparse O
linear O
discriminant O
analysis O
( O
sLDA O
) O
on O
nodal O
strength O
values O
was O
performed O
on O
patients O
only O
to O
investigate O
whether O
distinct O
brain O
connectivity O
features O
can O
be O
associated O
with O
distinct O
clinical O
stages O
. O

Leave-one-out O
cross O
validation O
( O
LOOCV O
) O
error O
and O
inter-class O
distances O
in O
the O
sLDA O
feature O
space O
were O
used O
as O
indicators O
of O
classes O
’ O
separability O
. O

In O
these O
analyses O
, O
sLDA O
was O
meant O
to O
explore O
the O
neuroimaging O
patterns O
characterizing O
the O
different O
early-psychosis O
stages O
, O
and O
not O
to O
generalize O
to O
a O
prediction O
setting O
. O

For O
further O
details O
see O
SI.5 O
, O
Figure O
S1 O
. O

